Omega Diagnostics turnover slightly ahead at the interim stage

The AIM-traded firm said turnover is expected to be £6.83m, 3% ahead of last year's first half in constant currency terms and 11% ahead of last year's result on an actual basis.

Its board said that reflected the weakening of sterling against the dollar and euro throughout the period.

Profit before tax, before share based payments, IFRS-related discount unwinds and amortisation of intangible assets, was in line with management's expectation at the half-year stage, it claimed.

On a segmental basis, Omega’s food intolerance division saw revenue of £3.84min the half year, up 15% from £3.34m, with allergy and autoimmune revenue up 11% to £1.76m.

Infectious disease and other reported revenue of £1.23m, a marginal 1% increase on the £1.22m it posted at the same stage last year.

“We are pleased with the positive progress that has been made in our key business areas and are looking to the future with increased confidence regarding commercialisation of CD4, the Allersys programme and the Malaria product range,” said CEO Andrew Shepherd.